Literature DB >> 34027475

Rapid and efficient enhancer cloning and in vivo screening using the developing chick embryo.

Ruth M Williams1, Tatjana Sauka-Spengler1.   

Abstract

Here, we describe a highly efficient, medium-throughput strategy for cloning and in vivo screening of putative enhancers using the chick embryo. By incorporating 48 unique nanotags for use in NanoString nCounter® across three different fluorescent reporters and developing a rapid and efficient digestion/ligation type IIs restriction enzyme-based cloning protocol, we develop a multiplexed approach for rapidly identifying enhancer activity. For complete details on the use and execution of this protocol, please see Williams et al. (2019).
© 2021 The Authors.

Entities:  

Keywords:  CRISPR; Gene Expression; Model Organisms; Molecular Biology

Mesh:

Year:  2021        PMID: 34027475      PMCID: PMC8121703          DOI: 10.1016/j.xpro.2021.100507

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

Selecting putative enhancer regions

We have found that chromatin accessibility analysis of specific cell types performed across different developmental timepoints yielded the best input data from which active enhancers can be identified. In short, we have used ATAC-seq to generate cell-type specific maps of putative regulatory elements of chick neural crest (NC) cells at two distinct stages of development, corresponding control non-NC cells, prospective NC progenitors during gastrulation, and, as an outlier population, another specific embryonic cell type (somites, myocardium etc.) (Williams et al., 2019). This approach provided us with a range of global chromatin accessibility profiles that can be used in unbiased clustering methods to identify dynamic spatiotemporal patterns of accessibility, thus enabling identification of tissue- and stage-specific elements for each population. Histone modifications and cross-species conservation are also useful parameters to consider for prediction of putative enhancers (Betancur et al., 2010; Rada-Iglesias et al., 2012; Simoes-Costa et al., 2012). Once candidate ATAC peaks are identified, primers should be designed to amplify the entire region underlying the peak +100 bp each way, this is generally ∼1 kb but some cloned enhancer elements may be up to 4 kb. This ensures all essential transcription factor binding sites are included, but potential repressor sites outside of the open region are excluded. If enhancer activity is observed, the region can be further trimmed down to identify the core element. Due to the significant level of conservation of enhancer function across amniotes, the chick system can be used to test and validate enhancer function of human cis-regulatory elements active during embryonic development (Hay et al., 2016; Hellner et al., 2016), and also to screen putative elements from other vertebrate species including zebrafish (unpublished data) and lamprey (Hockman et al., 2019).

Primer design

Timing: 5–15 min per primer pair We used Primer3 to predict target specific primers of approximately 20bp, with no off-target sites and no hairpin formation or self-complementarity. Ensure the sequence to be amplified does not contain any BsmBI sites (if this is unavoidable In-Fusion cloning should be used, see troubleshooting section). Primer tail sequences are provided in the table below. These include a BsmBI recognition site and excess sequence to facilitate enzyme binding, as well as appropriate overhangs to incorporate PCR amplicons into the reporter vector using BsmBI mediated cloning.

Nanotag reporter vectors

The Nanotag enhancer reporter vectors, including positive and negative controls, generated in the associated study can be obtained from Addgene. https://www.addgene.org/Tatjana_Sauka-Spengler/

Key resources table

Step-by-step method details

Cloning putative enhancers

Timing: 3 days PCR amplification of putative enhancers Timing: 2–3 h Digestion/ligation reaction Timing: 3 h Plasmid safe treatment to remove linearized vector Timing: 1.5 h Colony screening Timing: 1.5 h This protocol has been developed and optimized to facilitate rapid cloning of large numbers of enhancers in a streamlined, efficient manner. The vectors accompanying this protocol carry either Citrine, Cerulean or mCherry fluorescent reporters as well as one of 48 unique Nanotag sequences allowing multiplex testing of enhancers using Nanostring technology. The cloning insertion site contains the lacZ expression cassette flanked by asymmetric recognition sites for type IIS restriction enzyme BsmBI. Putative enhancers are amplified using primers extended by tails that contain the asymmetric BsmBI recognition site and specific cleavage sequences that will produce the sticky-end overhangs corresponding precisely to the ones remaining in the vector following BsmBI digestion. As a type IIS enzyme BsmBI cleaves outside its recognition sequence, the binding site is lost in both the vector and the amplified enhancer fragment following their ligation, precluding the re-digestion of the ligated constructs containing the intended fragment (Figure 1). As such the digestion-ligation reaction can be performed simultaneously in the same tube, using a modified GoldenGate assembly cycling reaction. During the digestion-ligation steps, the lacZ cassette is excised and the putative enhancer is inserted in a highly efficient fashion. Self-annealing of the vector does not occur as the overhangs generated by the excision of the lacZ cassette are not compatible. Positive colonies can then be easily identified by blue/white selection.
Figure 1

Modified reporter plasmids for highly efficient enhancer cloning

(A) Modified pTK enhancer reporter vector containing Nanotag barcode downstream of the fluorescent reporter, but upstream of the polyA tail. BsmBI recognition sites flanking lacZ cassette are also shown.

(B) Sequence details of BsmBI mediated cloning of amplified putative enhancer regions into the modified pTK vector. Figure adapted and reprinted with permission from (Williams et al., 2019).

PCR amplification of putative enhancers Amplify putative enhancer sequences from genomic DNA (gDNA) using a high-fidelity polymerase of your choice. We recommend Kapa LongRange and describe the conditions below. ∗Adjust according to primer Tm Run PCR samples on 1% agarose gel and gel purify. We used Promega Wizard SV gel and PCR clean-up system (A9282). Quantify on Nanodrop. Pause point: purified PCR’s can be stored at −20°C. Digestion/Ligation reaction Set up digestion/ligation reaction as below in 0.2 mL PCR tubes. Run the digestion/ligation reaction in a thermal cycler CRITICAL: Be sure to select the correct fluorescent reporter vector corresponding to the primers used to generate PCR products. Use different Nanotag vectors for each enhancer to be tested by Nanostring. Plasmid safe treatment to remove linearized vector Set up the plasmid safe reaction as below Transformation. PlasmidSafe™ or digestion/ligation reactions can be directly transformed into competent cells of your choice. We used DH10B. Colony Screening. This approach is only suitable for enhancers >500 bp, owing to the limited resolution of plasmid lysates by gel electrophoresis. Alternatively, colonies can be screened by PCR or constructs can be directly mini-prepped and checked by sequencing without a screening step. For optimal results grow colonies to approximately 1 mm in diameter. Screen ∼6 colonies per putative enhancer. Prepare 1% agarose gel, do not cover with TAE buffer. Add 10 μL of Qiagen buffer P1 to each PCR tube or well of 96 plate to be used. Using a sterile tip, touch selected colony, streak onto a new plate (multiple colonies can be streaked on a single plate marked out into a grid) and place tip in tube/well containing P1. Resuspend cells in P1 by gently agitating tips. Remove tips. Add 10 μL buffer P2 and seal tubes/plate and heat at 60°C for 15 min in a PCR cycler. Add 5 μL of 6× gel loading buffer. Load samples onto gel ‘dry’ i.e., add only enough TAE running buffer to reach the sides of the gel, buffer should not cover the gel surface as the reaction mix does not sink in the buffer. Run electrophoresis for 2–5 min until samples have entered the gel then more running buffer can be added. Discriminate positive colonies by comparing to super-coiled ladder. Nanotag reporter vectors with lacZ are 5 kb. Prepare Endotoxin free preps of positive colonies. We used Qiagen EndoFree Maxi kit (#12362) or Omega BioTek EZNA Endofree plasmid mini prep II (VWR #D6950-02) and Sanger sequence using pTK Forward and pTK Reverse primers (see key resources table). Pause point: Endotoxin-free preps can be stored at −20°C until enough are ready for electroporation. Modified reporter plasmids for highly efficient enhancer cloning (A) Modified pTK enhancer reporter vector containing Nanotag barcode downstream of the fluorescent reporter, but upstream of the polyA tail. BsmBI recognition sites flanking lacZ cassette are also shown. (B) Sequence details of BsmBI mediated cloning of amplified putative enhancer regions into the modified pTK vector. Figure adapted and reprinted with permission from (Williams et al., 2019).

Electroporation of enhancer constructs into early chick embryos

Timing: 2–6 h Nanotagged putative enhancer preps are now ready to be pooled and electroporated into early chick embryos. Electroporated embryos are allowed to grow to the desired stage such that in vivo enhancer reporter activity can develop and be subsequently quantified using Nanostring nCounter system®. These same steps are then followed to electroporate combinations of 1-3 positive enhancers from the Nanostring screen driving different fluorophores and imaged to record specific spatial and temporal enhancer activity. Combine Nanotag plasmids containing putative enhancers. Plasmids with unique Nanotags should be combined at equal concentration (∼0.5 μg/μL), to a final concentration of 6 μg/μL in water (this is the maximum concentration chick embryos can reasonably tolerate), this equates to 10–12 plasmids including controls. We provide a number of Nanotag reporter plasmids containing the FoxD3 neural crest enhancer (NC1) (Simoes-Costa et al., 2012) as positive control (Addgene #130570 - #130573). If this is not suitable, we have also made other tested chick enhancers available (Addgene #130574 - #130625). Some of these are more broadly active across chick embryonic tissues and stages, see (Williams et al., 2019) for specific expression patterns. We also provide several Nanotag reporter plasmids containing a short non-specific sequence to be used as negative control (Addgene #130558 - #130568). All controls were generated in a variety of Nanotags to facilitate flexibility in the pooling. CRITICAL: Ensure pooled plasmids contain unique Nanotags. Add vegetable dye to visualize solution during electroporation. Electroporate pooled plasmids into early chick embryos. We describe this process in detail in the ‘Ex ovo electroporation of early chicken embryos’ protocol associated with (Williams et al., 2019). Inject ∼1 μL pooled plasmid solution into the entire epiblast of HH4 (Hamburger and Hamilton, 1951) chick embryos. At HH4, cells of ectodermal origin will be successfully transfected, if mesoderm or endoderm derivatives are targeted, electroporation should be performed at HH3, however this does impede survival so higher number of embryos should be used. Electroporate using platinum plate electrodes and settings 5V, 100 ms ON, 50 ms OFF for 5 pulses. Grow embryos on thin albumin at 37°C until desired stage is reached. Dissect the tissue of interest. Isolation of specific cells is not necessary at this screening stage, but using dissected tissue will enrich for cells likely to harbour enhancer activity and thus provide more robust readout. Using whole embryos may result in false negatives due to dilution of enhancer positive cells.

NanoString assay

Timing: RNA extraction = 30 min hands on plus 1 h Turbo DNase incubation Nanostring sample preparation = 30 min Nanostring nCounter Prep station = 2 h Nanostring nCounter digital analyser = 4 h In this step RNA is extracted from the embryonic tissue of interest and subsequently hybridized with Nanostring probes such that enhancer reporter activity can be quantified using Nanostring nCounter®. Prepare dissected tissue for RNA extraction. We recommend Ambion RNAqueous™-micro total RNA isolation kit (AM1931). Place dissected tissue directly into 100 μL lysis buffer, in a low-bind 1.5 mL tube, minimizing the amount of media added with tissue. Keep on ice for 15 min and vortex for 5 s intermittently. Flash freeze in liquid nitrogen and store at −80°C. Pause point: Dissected tissue can be stored in lysis buffer at −80°C for up to 3 months. Extract RNA from dissected tissue Follow RNA extraction protocol. Elute RNA with 2× 10 μL EB from the kit. Add 2 μL Turbo DNase (AM1907) to 20 μL of eluted RNA. Incubate at 37°C for 1 h. Add 2 μL resuspended inactivation reagent (AM1931) to DNase reaction and flick to mix. Incubate at 20°C–24°C for 2 min, flicking after one minute to maintain solution. Centrifuge at 10,000 g for 1.5 min, remove supernatant into new DNase/RNase free low-binding tube, careful not to take any pelleted inactivation reagent. Verify the integrity of RNA using Agilent Bioanalyzer or Tapestation. Use 100 ng high quality (RIN >7) RNA for Nanostring analysis. Hybridize samples with Nanostring CodeSet according to the manufacturer’s protocol (MAN-10056-03_CodeSet_hybridization_Setup). Load samples into the nCounter® prep station and subsequently run the chip on the digital analysis system following the manufacturer’s instructions (MANC0035_nCounter_Analysis_System_MAX_FLEX). This manual also provides details for extracting and processing data files. Nanostring nCounter® output data provides a simple count of mRNA transcripts detected by the custom CodeSet (Figure 2). By incorporating positive and negative controls, active enhancer candidates can be resolved. Typically, positive controls recorded counts between 600–900 and negative control counts were below 10 (Figure 2). We empirically determined that enhancers with a count above 100 drove fluorescent reporter activity in vivo. We found minimal variance between different Nanotag reporters containing the same enhancer.
Figure 2

Nanostring screening of putative enhancers

(A) Nanotag transcripts are detected by a customized Nanostring codeset (Table S1), counts above 100 (in green, above dashed line) were determined to depict in vivo enhancer activity.

(B) Negative control plasmids achieved Nanostring counts less than 100. In vivo background expression is observed in the posterior extra-embryonic region.

(C) Enhancers with Nanostring count >100 are re-electroporated into early chick embryos at higher concentration such that fluorescence can be observed. Multiple enhancers carrying different fluorophores can be imaged in parallel, as shown for neural crest enhancers; NC1, NC2 and Sox10E2 (Betancur et al., 2010; Simoes-Costa et al., 2012). Figure adapted and reprinted with permission from (Williams et al., 2019).

Electroporate candidate enhancers individually, or in combination of different fluorophores, into early chick embryos as step 6, but at higher concentration (2 μg/μL per enhancer) record spatiotemporal enhancer activity by confocal microscopy. Nanostring screening of putative enhancers (A) Nanotag transcripts are detected by a customized Nanostring codeset (Table S1), counts above 100 (in green, above dashed line) were determined to depict in vivo enhancer activity. (B) Negative control plasmids achieved Nanostring counts less than 100. In vivo background expression is observed in the posterior extra-embryonic region. (C) Enhancers with Nanostring count >100 are re-electroporated into early chick embryos at higher concentration such that fluorescence can be observed. Multiple enhancers carrying different fluorophores can be imaged in parallel, as shown for neural crest enhancers; NC1, NC2 and Sox10E2 (Betancur et al., 2010; Simoes-Costa et al., 2012). Figure adapted and reprinted with permission from (Williams et al., 2019).

Expected outcomes

Following enhancer cloning using our modified GoldenGate BsmBI strategy we generally find >90% of colonies yield accurate sequencing results. Using ATAC-seq datasets from a range of cell-types and performing comparative analysis we found approximately 75% of selected putative enhancers were indeed active in vivo.

Limitations

Currently high-throughput screening for enhancer activity depends on Nanostring nCounter® technology. In the absence of such resources it is feasible to use qPCR to detect Nanotag barcodes, however this approach has not optimized. While Nanostring technology can detect up to 800 transcripts in a single sample, we have only optimized 48 different Nanotags. As these can be multiplexed in the embryo and up to 12 samples can be run on a single Nanostring chip we found this more than sufficient to screen over 500 putative enhancers.

Troubleshooting

Problem 1

BsmBI restriction sites within putative enhancer regions

Potential solution

In this scenario In-Fusion® HD Cloning kit is recommended, (Takara Clontech #639649). Nanotag reporter vectors are digested with BsmBI and PCR amplicons are generated with the following tails. In-Fusion® cloning protocol: Digest Nanotag reporter vector with BsmBI Gel purify digested vector Amplify putative enhancer regions as described above Set up the In-Fusion® reaction as follows Immediately place reaction on ice and proceed directly to transformation

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tatjana Sauka-Spengler tatjana.sauka-spengler@imm.ox.ac.uk

Materials availability

Plasmids generated in this study have been deposited to Addgene. https://www.addgene.org/Tatjana_Sauka-Spengler/ Custom Nanotag Nanostring codeset is available from Nanostring technologies, sequences are provided here in a Table S1.

Data and code availability

Original/source data for figures in the paper is available (Williams et al., 2019)
REAGENT or RESOURCESOURCEIDENTIFIER
Biological samples

Fertilized chicken eggsHenry Stewart & Co LtdN/A

Chemicals, peptides, and recombinant proteins

Kapa long range polymeraseKapa Biosystems#KK3501
Kapa HiFi polymeraseKapa Biosystems#KK2103
BsmBINew England Biolabs#R0580L
T4 DNA ligaseNew England Biolabs#M0202S
PlasmidSafe™Cambio#E3101K
In-Fusion® HD Cloning KitTakara Clontech#639649

Critical commercial assays

EndoFree Maxiprep KitQIAGEN#12362
E.Z.N.A. EndoFree mini prep kit IIVWR (Omego Bio-Tek)#D6950-02
Wizard SV Gel and PCR Clean-up SystemPromega#A9282
RNAqueous™-Micro Total RNA Isolation KitAmbion#AM1931
TURBO™ DNaseAmbion#AM1907

Deposited data

Nanotagged reporter vectorshttps://www.addgene.org/Tatjana_Sauka-Spengler/IDs 130514 - 130573
Selected positive enhancershttps://www.addgene.org/Tatjana_Sauka-Spengler/IDs 130625 - 130574

Oligonucleotides

Cerulean forwardTTTTTTCGTCTC ccatgg nnnnnnnnnnnnnnnnnnnnN/A
Cerulean reverseTTTTTTCGTCTC ggtcct nn+nnnnnnnnnnnnnnnnnnN/A
Citrine forwardTTTTTTCGTCTC gccagg nnnnnnnnnnnnnnnnnnnnN/A
Citrine reverseTTTTTTCGTCTC caacag nnnnnnnnnnnnnnnnnnnnN/A
Cherry forwardTTTTTTCGTCTC gtgcag nnnnnnnnnnnnnnnnnnnnN/A
Cherry reverseTTTTTTCGTCTC caccgt nnnnnnnnnnnnnnnnnnnnN/A
Inf. Cerulean forwardAGCTCGAGTT ccatg nnnnnnnnnnnnnnnnnnnnN/A
Inf. Cerulean reverseCCGGGCTAGC ggtcc nnnnnnnnnnnnnnnnnnnnN/A
Inf. Citrine forwardAGCTCGAGTT gccag nnnnnnnnnnnnnnnnnnnnN/A
Inf. Citrine reverseCCGGGCTAGC caaca nnnnnnnnnnnnnnnnnnnnN/A
Inf. Cherry forwardAGCTCGAGTT gtgca nnnnnnnnnnnnnnnnnnnnN/A
Inf. Cherry reverseCCGGGCTAGC caccg nnnnnnnnnnnnnnnnnnnnN/A
pTK forwardCTAGCAAAATAGGCTGTCCCN/A
pTK reverseATATTTCTTCCGGGGACACCN/A

Other

Nanostring plasticware and reagentsNanoString TechnologiesNAA-PPCK-048
NanoString custom probe set (see Table S1)N/A
Volume (μL)Reagent
27.5Water
2.0gDNA (100 ng)
10.05× buffer Long Range (no MgCl2)
3.5MgCl2 (25 mM)
1.5dNTPs (10 mM)
0.5KAPA LR enzyme
2.5F primer (10 μM)
2.5R primer (10 μM)

∗Adjust according to primer Tm

Volume (μL)Reagent
75 ngPCR product
75 ngNanotag reporter vector
2.0T4 DNA ligase buffer
1.0T4 DNA ligase (NEB, M0202)
1.0BsmBI (NEB, R0508)
Up to 20 μLWater
Temperature (°C)Time (min)# cycles
37525
1610
555
805
Volume (μL)Reagent
10.25Digestion/ligation reaction
1.25PlasmidSafe™ buffer (Cambio E3101K)
0.5ATP (25 mM)
0.5PlasmidSafe™ enzyme

In-Fusion® cloning protocol:

Volume (μL)Reagent
1 μgNanotag reporter vector
10.0NEB buffer 3.1
1.0 (10U)BsmBI
Up to 100 μLWater
Volume (μL)Reagent
100 ngPCR product
100 ngDigested vector
2.05× In-Fusion® mix
Up to 10 μLwater
  9 in total

1.  Genomic code for Sox10 activation reveals a key regulatory enhancer for cranial neural crest.

Authors:  Paola Betancur; Marianne Bronner-Fraser; Tatjana Sauka-Spengler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-05       Impact factor: 11.205

2.  A series of normal stages in the development of the chick embryo.

Authors:  V HAMBURGER; H L HAMILTON
Journal:  J Morphol       Date:  1951-01       Impact factor: 1.804

3.  Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest.

Authors:  Alvaro Rada-Iglesias; Ruchi Bajpai; Sara Prescott; Samantha A Brugmann; Tomek Swigut; Joanna Wysocka
Journal:  Cell Stem Cell       Date:  2012-09-13       Impact factor: 24.633

4.  Genetic dissection of the α-globin super-enhancer in vivo.

Authors:  Christian Babbs; James O J Davies; Bryony J Graham; Lars Hanssen; Mira T Kassouf; A Marieke Marieke Oudelaar; Jacqueline A Sharpe; Maria C Suciu; Jelena Telenius; Ruth Williams; Deborah Hay; Jim R Hughes; Christina Rode; Pik-Shan Li; Len A Pennacchio; Jacqueline A Sloane-Stanley; Helena Ayyub; Sue Butler; Tatjana Sauka-Spengler; Richard J Gibbons; Andrew J H Smith; William G Wood; Douglas R Higgs
Journal:  Nat Genet       Date:  2016-07-04       Impact factor: 38.330

5.  Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.

Authors:  Karin Hellner; Fabrizio Miranda; Donatien Fotso Chedom; Sandra Herrero-Gonzalez; Daniel M Hayden; Rick Tearle; Mara Artibani; Mohammad KaramiNejadRanjbar; Ruth Williams; Kezia Gaitskell; Samar Elorbany; Ruoyan Xu; Alex Laios; Petronela Buiga; Karim Ahmed; Sunanda Dhar; Rebecca Yu Zhang; Leticia Campo; Kevin A Myers; María Lozano; María Ruiz-Miró; Sónia Gatius; Alba Mota; Gema Moreno-Bueno; Xavier Matias-Guiu; Javier Benítez; Lorna Witty; Gil McVean; Simon Leedham; Ian Tomlinson; Radoje Drmanac; Jean-Baptiste Cazier; Robert Klein; Kevin Dunne; Robert C Bast; Stephen H Kennedy; Bassim Hassan; Stefano Lise; María José Garcia; Brock A Peters; Christopher Yau; Tatjana Sauka-Spengler; Ahmed Ashour Ahmed
Journal:  EBioMedicine       Date:  2016-07-02       Impact factor: 8.143

6.  Reconstruction of the Global Neural Crest Gene Regulatory Network In Vivo.

Authors:  Ruth M Williams; Ivan Candido-Ferreira; Emmanouela Repapi; Daria Gavriouchkina; Upeka Senanayake; Irving T C Ling; Jelena Telenius; Stephen Taylor; Jim Hughes; Tatjana Sauka-Spengler
Journal:  Dev Cell       Date:  2019-10-21       Impact factor: 12.270

7.  A genome-wide assessment of the ancestral neural crest gene regulatory network.

Authors:  Dorit Hockman; Vanessa Chong-Morrison; Stephen A Green; Daria Gavriouchkina; Ivan Candido-Ferreira; Irving T C Ling; Ruth M Williams; Chris T Amemiya; Jeramiah J Smith; Marianne E Bronner; Tatjana Sauka-Spengler
Journal:  Nat Commun       Date:  2019-10-16       Impact factor: 14.919

8.  Dynamic and differential regulation of stem cell factor FoxD3 in the neural crest is Encrypted in the genome.

Authors:  Marcos S Simões-Costa; Sonja J McKeown; Joanne Tan-Cabugao; Tatjana Sauka-Spengler; Marianne E Bronner
Journal:  PLoS Genet       Date:  2012-12-20       Impact factor: 5.917

9.  Barcoded DNA-tag reporters for multiplex cis-regulatory analysis.

Authors:  Jongmin Nam; Eric H Davidson
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  9 in total
  1 in total

1.  Investigating chromatin accessibility during development and differentiation by ATAC-sequencing to guide the identification of cis-regulatory elements.

Authors:  Emily Louise Smith; Gi Fay Mok; Andrea Münsterberg
Journal:  Biochem Soc Trans       Date:  2022-06-30       Impact factor: 4.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.